Open access · CC-BY
via OpenAlex
Serum Biomarkers for Inflammatory Bowel Disease
Peng Chen, Gaoshi Zhou, Jingxia Lin, Li Li, Zhirong Zeng, Minhu Chen, Shenghong Zhang
Frontiers in Medicine · 2020 · ▲ 193 citations
Abstract
Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment is urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study since they are non-invasive, convenient, and relatively inexpensive compared to using markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using pre-defined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely-used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, non-coding RNAs), and also recently advance in serological biomarkers (e.g., metabolomics, proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, there is still no ideal serum biomarkers for IBD to date. Serum profiling and non-coding RNAs are just started to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fmed.2020.00123
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Chen, P., Zhou, G., Lin, J., Li, L., Zeng, Z., Chen, M., & Zhang, S. (2020). Serum Biomarkers for Inflammatory Bowel Disease. <em>Frontiers in Medicine</em>. https://doi.org/10.3389/fmed.2020.00123
Vancouver
Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, et al. Serum Biomarkers for Inflammatory Bowel Disease. Frontiers in Medicine. 2020. doi:10.3389/fmed.2020.00123.
BibTeX
@article{peng2020SerumB,
title = {Serum Biomarkers for Inflammatory Bowel Disease},
author = {Peng Chen and Gaoshi Zhou and Jingxia Lin and Li Li and Zhirong Zeng and Minhu Chen and Shenghong Zhang},
journal = {Frontiers in Medicine},
year = {2020},
doi = {10.3389/fmed.2020.00123},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Medicinal Research Reviews 2022
Preprint · OA
Inflammatory bowel disease biomarkers
Disease Markers 2014
Open access · CC-BY
Biomarkers of Inflammatory Bowel Disease
Beijing Tiantan Hospital 2023
Open access · US-GOV
Establishment of Chinese Brain Charts for Individualized Diagnosis of Major Brain Diseases
Frontiers in Medicine 2019
Open access · CC-BY
A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease
Molecular Neurodegeneration 2015
Open access · CC-BY
Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
Experimental Dermatology 2016
Open access · OA